What drug a GLP-1 price is for
A price is only a price about something. Across 3018 figures published on 408 GLP-1 sellers’ own pages, 845 do not identify the drug they price — and 523 sit on a page that never scopes them to one. This page counts both, and explains why not one of those numbers appears as a price anywhere on this site.
Reviewed by Ellis Brandt. Sources checked September 2026.
What the figures name
Each of the 3018 figures was read with the words around it, by a person, and recorded against the drug those words name. Four outcomes, summing to 3018.
Share of the 3018 distinct published figures. Each figure is counted once, and the count is of figures rather than sellers.
Read from each seller’s own public pages, September 2026. Every figure classified by reading the seller’s own words around it; see how we grade.
337 figures say a GLP-1 and stop. That is not a small category, and it is not an accident: “GLP-1” is a class of drug, and a class is what a page says when it wants a number to look like an offer without committing to what the offer is. Semaglutide and tirzepatide are not interchangeable, they are not priced alike, and their labels do not say the same things — what the FDA-approved labels state about each is on this site with no company named, and so is the question a class name invites: whether any of it is insulin.
Which brand-name drugs get a price
320 of the 3018 figures name one of 6 brand-name products. These are the only figures on which the question this page asks has already been answered by the drug’s own name.
Share of the 320 figures that name a brand-name product. Sums to that number, not to 3018.
Read from each seller’s own public pages, September 2026.
A brand name is a trademark of its manufacturer and is used here only to identify the product a seller’s own page named. This site is not affiliated with any of them; see trademarks.
Where the figure was read
A second question, asked of the same 3018 figures: was the number read on a page about one drug, or on a general page — a home page, a pricing page, a landing page — that happens to mention a GLP-1 somewhere near it?
On a page scoped to one drug
2495 of 3018 — The page itself establishes what the figure is for.
On a general or home page
523 of 3018 — Only the words immediately around the number tie it to a drug, and a short quotation cannot carry that proof to a reader.
Read from each seller’s own public pages, September 2026.
523 figures were read on a general or home page. This site prints none of them, and the reason is not that they are wrong. It is that they are unshowable: to publish a figure honestly you have to be able to quote the words that make it true, and on a home page carrying several drugs, several plans and several prices, no short quotation proves which number goes with which drug. A page that printed them anyway would be asking a reader to trust a tie it could not show.
The same question, asked once per seller
Everything above counts figures. This section counts sellers, and it counts 408 of them — the ones that published at least one figure naming a GLP-1, not the 588 whose pages were opened and not the roster.
Share of the 408 sellers publishing at least one figure tied to a GLP-1. Rows overlap: a seller can appear in more than one.
Read from each seller’s own public pages, September 2026.
56 sellers never name a drug beside any figure they publish, and 115 have no page about a drug at all. Against that, 94 publish at least one figure naming a brand-name product and 304 publish at least one naming semaglutide or tirzepatide. The rows overlap on purpose: a seller can name a drug on one page and not on another, and collapsing that into a single verdict per company would hide the thing worth knowing.
Why none of these numbers is printed as a price
Not one amount appears on this page, and the module behind it holds none. That is a rule, not an omission. A figure earns a place on this site when three things can be shown at once: the seller’s own words contain the number, those words identify the drug, and the qualifier that makes the number true can be printed beside it.
Most of these 3018 figures fail the second test, and there is no fixing it by reading harder. Where the tie between a number and a drug rests on layout — a heading three blocks up, a tab that was open when the page loaded — the tie is real to a person sitting in front of the page and cannot be carried to a reader in a quotation. The honest response is to count them and print the count, which is what this page is.
Prices on this site come from the 61 sellers whose figure states what it buys, each shown with the seller’s own qualifier attached. How many sellers that is out of, and every rule that narrows one number to the other, is on how many GLP-1 sellers publish a price.
The other findings
Each one says how many sellers it counted, and the counts differ on purpose: a question can only be asked of the sellers who published enough to answer it.
- How many sellers publish a price
What happened when the pages of every GLP-1 seller we could find were opened and read: how many published a figure at all, and how many published one that can be compared.
Counted over 588 sellers whose pages were opened.
- Compounded or branded
How often a seller says, beside the figure, whether the drug is compounded or the FDA-approved product — and the one case where it almost always does.
Counted over 3018 published figures across 408 sellers.
- What sellers do not publish
The pharmacy, the product class, the dose schedule and the cancellation terms: four things a reader needs before buying, and how many sellers publish each one.
Counted over 61 sellers whose figure states what it buys.
- The tirzepatide premium
What the same seller charges for tirzepatide against semaglutide — and why most sellers who sell both do not publish a pair a reader can put side by side.
Counted over 46 sellers publishing a figure for both molecules.
- What a price buys, by dose
Whether a GLP-1 price changes with the dose, and how many sellers publish a figure that states which dose it buys at all.
Counted over 61 of 117 sellers on this roster.
What the FDA labels say
What each of these drugs is approved to treat, how its dose escalates and who should not take it is read from the FDA-approved prescribing information, with no company named and no paid link.
- First-year GLP-1 costsresearch guide
A low monthly headline does not tell you what a year of treatment will cost. Compare the same medication and service package, then separate the total you expect to spend from the amount you must pay before treatment begins.
- Cancellation and refundsresearch guide
Canceling future membership charges, stopping an upcoming medication order and requesting a refund are three different requests. Get a written answer for each one that applies to you.
- Insurance denial documentsresearch guide
The next step depends on why coverage was denied. A missing document, a formulary restriction and an excluded benefit are different problems. Start with the written decision before paying someone to submit another request.
- Savings and cash-pay eligibilityresearch guide
A manufacturer savings card and a self-pay offer can have different eligibility rules, even for the same medicine. Match the offer to your coverage and exact product before using its advertised price in your budget.
- Verify your GLP-1 pharmacyresearch guide
The website taking your payment, the clinician prescribing and the pharmacy dispensing may be different businesses. Identify each one. A recognizable brand or a reassuring badge does not tell you who will fill the prescription.
- Changing GLP-1 providersresearch guide
Before ending your current service, establish what the new practice needs, what it will charge and when it can evaluate you. Transferring your records does not guarantee that another clinician will continue the same prescription.
- Weight regain after stoppingresearch guide
Weight regain occurred after treatment withdrawal in studies of semaglutide and tirzepatide. The findings support planning follow-up and affordability before an interruption, but they do not predict exactly what will happen to one person.
- Semaglutide vs tirzepatideresearch guide
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- How they workresearch guide
The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.
- Is Ozempic insulin?research guide
What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.
- Zepbound vs Ozempicresearch guide
Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.
- Dose escalation schedulesresearch guide
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesresearch guide
What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.
- Hair lossresearch guide
Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.
- Fatigue and tirednessresearch guide
Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.
- Missed dose rulesresearch guide
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsresearch guide
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlineresearch guide
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Zepbound by doseresearch guide
What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.
- Zepbound at 3 monthsresearch guide
What does the Zepbound label report about three-month weight loss and maintenance dosing?
- Injecting tirzepatideresearch guide
The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.
- Refrigeration and storageresearch guide
How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.
- Who should not take oneresearch guide
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.
Where the comparable sellers are compared
One board per buying decision, built only from the sellers whose figure names a drug and states what it buys.
- Semaglutide providers55 listed
Compare semaglutide plans, pharmacy details and cancellation terms.
- Tirzepatide providers52 listed
Compare tirzepatide plans, pharmacy details and cancellation terms.
- Providers that publish a price before the intake60 listed
See providers that show medication prices before the intake.
- GLP-1 providers with a published price, compared60 listed
Compare advertised prices, plan commitments and what’s included.
- GLP-1 providers for readers paying cash53 listed
Compare plans whose published price includes medication.
- GLP-1 telehealth providers61 listed
Compare GLP-1 prescribers, pharmacy details, care and cancellation terms.
Every board above was read September 2026 and carries its own dated, counted title.